PG
TEVA icon

Patten Group’s Teva Pharmaceuticals TEVA Stock Holding History

Patten Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,000
Closed -$44.3K – 634
2016
Q3 		$44.3K Buy
1,000
+999
+99,900% +$52.1K 0.02% 331
2016
Q2 		$50 Hold
1
– – ﹤0.01% 637
2016
Q1 		$53 Hold
1
– – ﹤0.01% 671
2015
Q4 		$65 Hold
1
– – ﹤0.01% 697
2015
Q3 		$56 Hold
1
– – ﹤0.01% 598
2015
Q2 		$59 Buy
+1
New +$62 ﹤0.01% 595

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Patten Group's TEVA Position: Q4 2016 in Review

Patten Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 1,000 shares — an estimated $44.3K sold.

Patten Group first reported a position in TEVA in Q2 2015 and held it in 6 quarters. The position peaked at $44.3K in Q3 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Patten Group reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Patten Group sold 1,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $44.3K.
  • Patten Group first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Patten Group's Teva Pharmaceuticals position peaked at $44.3K in Q3 2016.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Patten Group's 13F filing for Q4 2016, filed 10 Feb 2017.